JBCHEPHARM JB Chemicals & Pharmaceuticals Q3 FY25 results (Oct–Dec 2024) and concall
J B Chemicals delivered a strong Q3 FY25 performance characterized by robust domestic growth and a sharp recovery in the CDMO segment. The company successfully navigated currency headwinds in Russia and softness in the US market through improved product mix and cost efficiencies. Management remains bullish on maintaining high-teen growth in India and mid-teen growth in CDMO over the medium term while guiding for steady operating margins.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|
| Revenue | 952 | 956 | 914 |
| EBITDA | 273 | 268 | 245 |
| Net profit | 173 | 173 | 156 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
